SVRA ▼ -20.2% - Savara Inc. $SVRA Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date 20-NOV-2026 08:30 AM ET